Primary neuroendocrine carcinoma of the breast
A single Center experience and review of the literature

Paolo Locurto, Angelo Danilo Antona, Antonietta Grillo, Antonio Ciulla, Stefania Martorana, Calogero Cipolla, Giuseppa Graceffa, Salvatore Vieni

A.O.U. Policlinico "Paolo Giaccone", Division of General and Oncological Surgery, University of Palermo, Palermo, Italy

Primary neuroendocrine carcinoma of the breast. A single Center experience and review of the literature

Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administered in patients with Ki-67>10%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.

KEY WORDS: Diagnosis, Neuroendocrine breast carcinoma

Introduction

Primary Neuroendocrine Breast Carcinomas (NEBC) are very rare malignant tumors. They were first described in 1977 by Cubilla and Woodruff and since then only a limited number of studies have been reported in literature. Primary NEBC representing about 0.1% of the total breast malignancies and they are very aggressive with tending to metastatize. According to the WHO Classification, primary NEBC is defined as a group of breast cancer morphologically similar to neuroendocrine tumors from gastrointestinal tracts or lungs. It was defined as an epithelial neoplasm with predominant neuroendocrine differentiation cells (50% or more of NE markers positivity). The histogenesis of NEBC is unclear but they are thought to arise from endocrine differentiation of a breast carcinoma rather than from preexisting endocrine cells in the breast. Much of the current limited knowledge of this disease is based on these small retrospective series and thus is subject to selection bias. Therefore, very little is known about the disease incidence, age and sex predilection, race/ethnicity distribution, clinic and pathologic characteristics and survival. The limited number of cases and a few studies currently available in the literature make difficult to establish a standard approach to treating this tumor, since only a
few case reports have indicated therapeutic options. The aim of this study was to apply pathological treatment modalities in clinical practice and to select the most appropriate treatment.

Material and Methods

Between 2007 and 2014, five women with primary NEBC were diagnosed and treated at the Policlinico Universitario “Paolo Giaccone” of Palermo, Department of Surgical Oncology. Four of these tumor were in the left breast, the other one in the right. The median age was 59.4 years (range 50-75). Patient characteristics are shown in Table I. Breast mass was evaluated by mammography and breast echotomography. All patients were submitted to core biopsy. Final diagnosis was made by pathological examination of surgical specimens obtained from the five patients. The specimens were fixed in formalin and routinely processed. The materials were stained with hematoxylin and eosin and later were examined using chromogranin, synaptophysin or neuron-specific enolase (NSE) antibodies (Fig. 1). A patient underwent mastectomy and four underwent quadrantectomy with biopsy of sentinel lymph node. The identification of sentinel lymph node was preoperative and intraoperative. In fact all patients, the day before surgery, underwent lymphoscintigraphy by means of a subareolar injection of tracer (Nanocoll). During surgery a gamma probe (Neoprobe 2000) was used in order to identify and remove the sentinel lymph node. In two case the sentinel lymph node was negative and in three cases axillary lymphadenectomy was performed. On the excised sentinel lymph node was first performed an intraoperative examination, then the definitive one. Moreover was performed an immunohistochemical analysis to define an eventually positivity to of steroid receptors, as well as, the expression of c-erbB2 and finally the grade of mitotic activity using the Ki-67 proliferative index. Following surgical treatment adjuvant chemotherapy and radiotherapy were administered to these patients. The Cisplatin and Etoposide combination was administered to all 4 patients with Ki 67 index > 40%. All patients were candidates for adjuvant radiotherapy with 6 MV photons, with a dose of 50 Gy (2Gy/fraction) to whole breast with tangential fields, and a subsequent additional dose of 10 Gy (2Gy/fraction) to the tumor bed. Each patient underwent a virtual CT-simulation, in supine position, using dedicated devices. The patient’s arms were raised above the head using an arm support in carbon fiber. The three-dimensional treatment plan was set with the Pinnacle® TPS system, the target volumes were delineated according to the criteria of the Radiation Therapy Oncology Group (RTOG) contouring atlas. All patients with estrogen and progesterone receptors positivity received hormonal therapy (Tamoxifen). All patients received psychological support.

Table I - Patients characteristics

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age</th>
<th>Location</th>
<th>TNM</th>
<th>Surgical Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>50</td>
<td>LEFT</td>
<td>T2N0M0</td>
<td>Quadrantectomy with biopsy of sentinel lymph node (-)</td>
<td>Alive, remission</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>LEFT</td>
<td>T2N1M0</td>
<td>Quadrantectomy and axillary lymphadenectomy</td>
<td>Alive, remission</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>LEFT</td>
<td>T2N1M0</td>
<td>Quadrantectomy and axillary lymphadenectomy</td>
<td>Alive, remission</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>LEFT</td>
<td>T2N1M0</td>
<td>Mastectomy and axillary lymphadenectomy</td>
<td>Dead</td>
</tr>
<tr>
<td>5</td>
<td>52</td>
<td>RIGHT</td>
<td>T2N0M0</td>
<td>Quadrantectomy with biopsy of sentinel lymph node (-)</td>
<td>Alive, remission</td>
</tr>
</tbody>
</table>

Fig. 1: Tumor staining. A) NE50: Hematoxylin-Eosin, 50x; B) NE100: Hematoxylin-Eosin, 100x; C) NECromo: Chromogranin positivity, 100x.
Primary neuroendocrine carcinoma of the breast. A single Center experience and review of the literature

Table II - Pathological and immunohistochemical characteristics of the tumors.

<table>
<thead>
<tr>
<th>Patients</th>
<th>T</th>
<th>N</th>
<th>ER(%)</th>
<th>PR(%)</th>
<th>GRADE</th>
<th>C-erbB2</th>
<th>Chrom.</th>
<th>Synop.</th>
<th>NSE</th>
<th>Ki-67(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.5</td>
<td>-</td>
<td>50</td>
<td>60</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>55</td>
</tr>
<tr>
<td>2</td>
<td>2.5</td>
<td>+</td>
<td>70</td>
<td>70</td>
<td>2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>60</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>+</td>
<td>90</td>
<td>80</td>
<td>2</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>&lt;10</td>
</tr>
<tr>
<td>4</td>
<td>4.5</td>
<td>+</td>
<td>80</td>
<td>70</td>
<td>3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>80</td>
</tr>
<tr>
<td>5</td>
<td>2.3</td>
<td>+</td>
<td>100</td>
<td>0</td>
<td>3</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>80</td>
</tr>
</tbody>
</table>

**Results**

Tumor size range was from 2.3 to 4.5 cm in diameter. Surgery was well tolerated and in all of them was performed sentinel lymph node technique in order to find axillary metastatic disease. Lymph node metastasis was detected in three patients and in two case lymph node sentinel was found negative. Estrogen and Progesterone receptors expression was found in all patients. Chromogranin and Synaptophysin expression was found highly positive in all of them and the patients expressed c-erbB2 too. The pathological characteristics of the patient are shown in Table II. In the post-operative time none of them developed lymphedema of the arm or any sensitivity disorders that are the most frequent collateral effect of this kind of surgery treatment. The patients were underwent four cycles of chemotherapy without collateral effects. Radiation therapy was feasible in all patients, no interruption of treatment was recorded in our experience. Heart and lung toxicity scoring was based on the common terminology criteria of adverse events (CTCAE). Scoring of breast/chest wall skin and subcutaneous toxicity used the Radiation Therapy Oncology Group (RTOG) acute (up to 1 month post radiotherapy) and late (after 1 month) morbidity scoring schemas. In our experience all five patients were treated with conventional treatment 3D CRT. At every week they were examined for acute toxicity at skin or others toxicity. Physical examination included also the evaluation of blood tests. The treatment was tolerated very well from all patients, with no acute toxicity. Then in all cases was administered Tamoxifen. Four patients are still alive and healthy, they are on a one year follow-up until they will reach the 5th year after surgery and then every 2 years. One patient dead.

**Discussion**

Neuroendocrine breast carcinomas (NEBC) include an heterogeneous group of tumors, showing morphological features similar to neuroendocrine tumors of the gut and lung, expressing one or more neuroendocrine markers in at least 50% of tumor cells. NEBC are rare lesions, representing about 0.1% of all breast cancers (BC) and according to World Health Organization (WHO) data mostly affect elderly patients. NEBC is characterized by less aggressiveness than the invasive ductal variant of BC, except for its small-cell variant. Epidemiologically, the incidence of NEBC appears to be controversial. NEBC almost exclusively affects female patients aged between the sixth and seventh decade; few cases are therefore diagnosed in the premenopausal period. Currently approximately 200 cases have been described in the literature, in the form of small series or as individual case reports, one of them in the bilateral type. A few cases in males have also been reported. Data related to the incidence of NEBC showed different percentages: from rare observations (0.09%) in the review by Fisher et al. in a series of 3,300 BC, to slightly higher according to Günhan-Bilgen et al. (2003) where they represent 0.27% of 1,845 BC cases, to Lopez-Bonet et al. reporting 0.51% of 1,368 patients. In the international scientific literature the first description of BC morphologically similar to intestinal carcinoids dates back to 1963 and is attributed to Feyrter and Hartmann. On the basis of argentic impregnation, Feyrter and Hartmann suggested the nature of endocrine “mucoid” carcinoma of the breast. However, it is commonly accepted that the first histopathological classification of NEBC, together with a clinical and prognostic analysis, is to be attributed to two American pathologists: Antonio Cubilla and James Woodruff in 1977. Since 2003, WHO defines NEBC as a separate entity, consisting of a varied group of breast primitive tumors of epithelial origin and morphology. In 2012, the last edition of World Health Organization (WHO) classification of breast and gynecologic tumors, described 4 main histologic types: solid (usually of low to intermediate grade), small/coat cell and large cell, that are both poorly differentiated variants and lately added atypical carcinoid tumor. NEBC are considered to derive from divergent differentiation (exocrine and endocrine) of a neoplastic epithelial progenitor cell during carcinogenesis, as opposed to a preexisting neuroendocrine stem cell theory. The diagnosis of NEBC needs immunohistochemistry positivity in at least 50% of the following markers in the tumor population (Table III). According to some authors, pre-surgery diagnosis of NEBC by fine-needle aspiration cytology (FNAC) is possible, though not without difficulty.
May–Grünwald–Giemsa staining shows moderate cellularity, low cohesiveness, with elements of polygonal shape and plasmacytoid, with abundant cytoplasm, oval nuclei and small nucleoli. Also, there is poor dimensional variation between the cell elements, but the decisive factor in the FNAC diagnosis appears to be the presence of cytoplasmic azurophilic granules, in particular in the cell periphery. More frequently, authors report histological identification of NEBC by aspiration core biopsy 29-32.

At present, however, such a diagnosis does not determine a treatment divergent from that of other histological types of BC. Compared to histologically different BCs, a peculiarity of NEBC is the occurrence of clinical conditions related to hormonal hypersecretion, although extremely rare. In fact, patients with symptoms related to ectopic secretion of ACTH, parathyroid hormone, prolactin, norepinephrine and calcitonin are described. These clinical presentations, however, are now considered exceptional and related to advanced tumor stages. These stages of diagnosis have decreased in the last decade, due to the diagnostic anticipation produced by the increasingly widespread of mammographic screening 33-35. At diagnosis, most patients are in their 60s or 70s, and there are no remarkable differences in the clinical presentation compared with other breast carcinomas 22,36. Tumor cells also show positivity for estrogen and progesterone receptors in well-differentiated tumors and in more than 50% of poorly differentiated small-cell carcinomas. However, the differential diagnosis of breast metastasis from neuroendocrine carcinoma of extra-mammary origin remains extremely challenging. Indeed, the rarity of these tumors does not allow large studies to be performed, and often such histologic entities are not included in large clinical trials of breast cancer treatment.

The gold-standard treatment is substantially similar to that for ductal-type carcinoma. Moreover, no specific treatment has been standardized in the adjuvant or metastatic settings for NEBC, although theoretically hormonal therapy should be included in the strategy according to the cellular receptor pattern 22,37. In terms of prognostic and predictive factors, HER-2 is almost always absent in NEBCs, while the vast majority express estrogen and/or progesterone receptors. The prognostic relevance of neuroendocrine differentiation is controversial, though most studies report a relatively poor prognosis based on the extent of the neuroendocrine component and the degree of its differentiation. The receptor status is most often of the Luminal A type: ER +, PR + and HER2 -; as described by Papotti, especially in non-small-cell subtypes 22,38. Neuroendocrine carcinomas do not present any particular imaging finding and, in many cases, the findings are comparable to the ones of other types of breast tumors. On mammography, as described by Ogawa, such tumors may present as well circumscribed lesions, with no associated microcalcifications, mimicking benign lesions 4,38. On ultrasonography, such tumors may present as either morphologically irregular solid lesions or lesions with a cystic component, with defined margins and increased vascularization. Also, in the present case, ultrasonography revealed the presence of a hypoechoicogenic mass with irregular morphology and defined contours, with no cystic component 39,40. MRI demonstrated, like in other cases described in the literature, the presence of an irregular lesion with early, intense, ring-enhancement, with morphological and kinetic characteristics of contrast uptake consistent with malignancy. Thus, despite the rarity of neuroendocrine carcinomas, with nonspecific imaging findings, such tumors should be included in the differential diagnosis of a nodular lesion with no associated microcalcifications on mammography and sonographically corresponding to a hypoechoicogenic mass with microlobulated or irregular contours 41,42. In our experience the subareolar injection of tracer to guide the accuracy of sentinel lymph node biopsy and the intraoperative frozen section examination of the node play an important role in the surgical management of the neuroendocrine breast carcinoma 43,44. The extension of surgery could have an impact on the well-being of physicians apart from the stress induced by surgery-related complications, this effect can be added to the impact in the patient's quality of life and clinical management 45.
Conclusion

Neuroendocrine tumors of the breast are rare. Due to the lack of distinguishing features on presentation and imaging they can be misdiagnosed. The diagnosis of NEBC is exclusively immunohistological expressing neuroendocrine markers in ≥ 50% of the cancer cells. In accord with other Authors, this trial shows that the gold-standard treatment is represented by surgical strategies, including breast-conserving surgery, as for usual-type breast cancers, associated to multidisciplinary approach with adjuvant chemotherapy and radiotherapy. However, because of the paucity of available literature on primary neuroendocrine carcinoma of the breast, their long-term prognosis and biologic behavior are not well known and the best treatment remains to be defined.

Riassunto

Il carcinoma neuroendocrino della mammella è un tumore estremamente raro. I casi riportati in letteratura sono molto pochi per cui la pianificazione del trattamento è ancora in discussione. Gli Autori riportano la loro esperienza su 5 casi osservati tra gennaio 2007 e dicembre 2014, insieme ad una revisione della letteratura. Quattro pazienti sono state sottoposte a quadrantectomia, in due delle quali è stata eseguita anche la linfadenectomia ascellare; in un solo caso è stata eseguita una mastectomia totale con linfadenectomia ascellare. In tutti i casi è stata utilizzata la colorazione con ematossilina-eosina ed è stata eseguita la valutazione immunistochimica della enolasi neuronospecifica (NSE), cromogranina, sinaptofisina, recettori per estrogeni e per progesterone. In 4 pazienti il valore del Ki-67 era >40%. Una chemioterapia adiuvante è stata somministrata nei casi con Ki-67 >10%; tutte le pazienti sono state sottoposte a radioterapia sulla mammella operata ed hanno effettuato ormonoterapia. Quattro pazienti sono state sottoposte a chirurgia per estrogeni e per progesterone. In 4 pazienti il valore del Ki-67 era >40%. Una chemioterapia adiuvante è stata somministrata nei casi con Ki-67 >10%; tutte le pazienti sono state sottoposte a radioterapia sulla mammella operata ed hanno effettuato ormonoterapia. Nonostante il tumore neuroendocrino della mammella sia considerato una entità distinta, il trattamento più adeguato sembra essere correlato alle dimensioni del tumore, allo status linfonodale ed al Ki-67, come per gli altri istotipi di carcinoma della mammella.

References


Carcinoma of the Breast. Diagnostic and clinical implications


